ArticleThe Journal of experimental medicine2021
Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs.
Erratum issuedOpen access · bronzeAbstract read
In one paragraph
Article in The Journal of experimental medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 88 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed, 2 pooled it
9.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 2 syntheses or guidelines pooled it, 127 citations in OpenAlex.
- Systematic Review and Meta-analysis of Anti-interferon Auto-antibodies in Infectious Diseases.Journal of clinical immunology · 2026Pooled it
- Exploring COVID-19 Pandemic Disparities with Transcriptomic Meta-analysis from the Perspective of Personalized Medicine.Journal of microbiology (Seoul, Korea) · 2024Pooled it
- Anti-Type I Interferon Autoantibodies in COVID-19 and Systemic Lupus Erythematosus: A Comparative Review.Antibodies (Basel, Switzerland) · 2026Review
- Human interferon-ω: an underappreciated type I interferon.Frontiers in immunology · 2026Review
- The seven enigmas of SARS-CoV-2: from the past to the future.Journal of human immunity · 2025Article
- The potential impacts of human genetics on virus emergence.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Differential response of human plasmacytoid pre-dendritic cells to SARS-CoV-2 variants.iScience · 2025Article
- Distinct circulating autoantibodies are associated with COVID-19 hospitalization and SARS-CoV-2 neutralization activity.Npj viruses · 2025Article
- Prevalence and association of type I IFN autoantibodies with clinical outcomes in critically ill Brazilian COVID-19 patients.Journal of human immunity · 2025Article
- Case-based evidence links increased SARS-CoV-2 diversity to impaired IFN-I response in severe COVID-19.Journal of human immunity · 2025Article
- Type I interferon autoantibody footprints reveal neutralizing mechanisms and allow inhibitory decoy design.The Journal of experimental medicine · 2025Article
- Paucity of viral infection symptoms in patients with immune-mediated inflammatory diseases.BMJ open · 2025Article
- Loss of tolerance precedes triggering and lifelong persistence of pathogenic type I interferon autoantibodies.The Journal of experimental medicine · 2024Article
- A genome-wide arrayed CRISPR screen identifies PLSCR1 as an intrinsic barrier to SARS-CoV-2 entry that recent virus variants have evolved to resist.PLoS biology · 2024Article
- In search of a function for human type III interferons: insights from inherited and acquired deficits.Current opinion in immunology · 2024Review
- The inflammatory microenvironment of the lung at the time of infection governs innate control of SARS-CoV-2 replication.bioRxiv : the preprint server for biology · 2024Article
- Anti-cytokine autoantibodies: mechanistic insights and disease associations.Nature reviews. Immunology · 2024Review
- Human autoantibodies neutralizing type I IFNs: From 1981 to 2023.Immunological reviews · 2024Review
- Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children.The Journal of experimental medicine · 2024Article
- Nasopharyngeal and Peripheral Blood Type II Interferon Signature Evaluation in Infants during Respiratory Syncytial Virus Infection.Medicina (Kaunas, Lithuania) · 2024Observational
28 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
23 authors at 4 institutions in 2 countries.
Jonathan Lopez *Molecular biology core facility, Civils Hospices of Lyon, Lyon Sud Hospital, Pierre-Bénite, France.ORCID 0000-0003-3768-2378
Marine Mommert *Joint Research Unit Civils Hospices of Lyon-bioMérieux, Civils Hospices of Lyon, Lyon Sud Hospital, Pierre-Bénite, France.ORCID 0000-0001-5624-7756
William Mouton *Joint Research Unit Civils Hospices of Lyon-bioMérieux, Civils Hospices of Lyon, Lyon Sud Hospital, Pierre-Bénite, France.ORCID 0000-0002-8455-0952
Andrés Pizzorno *International Center of Research in Infectiology, Institut National de la Santé et de la Recherche Médicale U1111, Centre National de la Recherche Scientifique UMR5308, École normale supérieure Lyon, Claude Bernard Lyon 1 University, Lyon, Rhône, France.ORCID 0000-0002-0918-6804
Karen Brengel-Pesce *Joint Research Unit Civils Hospices of Lyon-bioMérieux, Civils Hospices of Lyon, Lyon Sud Hospital, Pierre-Bénite, France.ORCID 0000-0001-8795-0647
Mehdi MezidiIntensive Care Medicine, Croix-Rousse hospital, Claude Bernard Lyon 1 University, Lyon, France.ORCID 0000-0002-8715-8323
Marine VillardInternational Center of Research in Infectiology, Institut National de la Santé et de la Recherche Médicale U1111, Centre National de la Recherche Scientifique UMR5308, École normale supérieure Lyon, Claude Bernard Lyon 1 University, Lyon, Rhône, France.ORCID 0000-0002-3905-8993
Bruno LinaInternational Center of Research in Infectiology, Institut National de la Santé et de la Recherche Médicale U1111, Centre National de la Recherche Scientifique UMR5308, École normale supérieure Lyon, Claude Bernard Lyon 1 University, Lyon, Rhône, France.ORCID 0000-0002-8959-2123
Jean-Christophe RichardIntensive Care Medicine, Croix-Rousse hospital, Claude Bernard Lyon 1 University, Lyon, France.ORCID 0000-0003-1503-3035
Jean-Baptiste FassierOccupational Health and Medicine Department, Hospices Civils de Lyon, Lyon, France.ORCID 0000-0003-3885-4987
Valérie CheynetJoint Research Unit Civils Hospices of Lyon-bioMérieux, Civils Hospices of Lyon, Lyon Sud Hospital, Pierre-Bénite, France.ORCID 0000-0001-6168-1821
Blandine PadeyInternational Center of Research in Infectiology, Institut National de la Santé et de la Recherche Médicale U1111, Centre National de la Recherche Scientifique UMR5308, École normale supérieure Lyon, Claude Bernard Lyon 1 University, Lyon, Rhône, France.ORCID 0000-0002-2159-6507
Victoria DuliereInternational Center of Research in Infectiology, Institut National de la Santé et de la Recherche Médicale U1111, Centre National de la Recherche Scientifique UMR5308, École normale supérieure Lyon, Claude Bernard Lyon 1 University, Lyon, Rhône, France.ORCID 0000-0003-2153-0927
Thomas JulienInternational Center of Research in Infectiology, Institut National de la Santé et de la Recherche Médicale U1111, Centre National de la Recherche Scientifique UMR5308, École normale supérieure Lyon, Claude Bernard Lyon 1 University, Lyon, Rhône, France.ORCID 0000-0002-8607-2827
Stéphane PaulInternational Center of Research in Infectiology, Institut National de la Santé et de la Recherche Médicale U1111, Centre National de la Recherche Scientifique UMR5308, École normale supérieure Lyon, Claude Bernard Lyon 1 University, Lyon, Rhône, France.ORCID 0000-0002-8830-4273
Paul BastardLaboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U1163, Necker Hospital for Sick Children, Paris, France.ORCID 0000-0002-5926-8437
Alexandre BelotOpen Innovation & Partnerships, bioMérieux S.A., Marcy l'Etoile, France.ORCID 0000-0003-4902-5332
Antonin BalIntensive Care Medicine, Croix-Rousse hospital, Claude Bernard Lyon 1 University, Lyon, France.ORCID 0000-0002-0261-2495
Jean-Laurent CasanovaLaboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U1163, Necker Hospital for Sick Children, Paris, France.ORCID 0000-0002-7782-4169
Manuel Rosa-CalatravaInternational Center of Research in Infectiology, Institut National de la Santé et de la Recherche Médicale U1111, Centre National de la Recherche Scientifique UMR5308, École normale supérieure Lyon, Claude Bernard Lyon 1 University, Lyon, Rhône, France.ORCID 0000-0002-7559-9527
Florence MorfinIntensive Care Medicine, Croix-Rousse hospital, Claude Bernard Lyon 1 University, Lyon, France.ORCID 0000-0002-1962-808X
Thierry WalzerInternational Center of Research in Infectiology, Institut National de la Santé et de la Recherche Médicale U1111, Centre National de la Recherche Scientifique UMR5308, École normale supérieure Lyon, Claude Bernard Lyon 1 University, Lyon, Rhône, France.ORCID 0000-0002-0857-8179
Sophie Trouillet-AssantInternational Center of Research in Infectiology, Institut National de la Santé et de la Recherche Médicale U1111, Centre National de la Recherche Scientifique UMR5308, École normale supérieure Lyon, Claude Bernard Lyon 1 University, Lyon, Rhône, France.ORCID 0000-0001-6439-4705
Université Claude Bernard Lyon 1 · FRHospices Civils de Lyon · FRHoward Hughes Medical Institute · USInserm · FR
Funding
Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational SuccessUL1TR001866 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY, KRUEGER, JAMES G · 2016 to 2025
$40.6MMonogenic basis of resistance to SARS-CoV2 and predisposition to severe COVID-19R01AI088364 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI Jean-Laurent Casanova, Shen-Ying Zhang · 2010 to 2026
$8.7MAgence Nationale de la RechercheAgence Nationale de la Recherche ANR-10-IAHU-01Agence Nationale de la Recherche ANR-20-C11-0001Agence Nationale de la Recherche ANR-20-COVI-0003Agence Nationale de la Recherche ANRS-COV05Centre National de la Recherche ScientifiqueClaude Bernard Lyon 1 UniversityÉcole normale supérieure de LyonEmergent VenturesFisher Center for Alzheimer's Research FoundationFondation ARC (équipe labellisée)Fondation des Hospices Civils de LyonFrench Foundation for Medical Research EQU201903007798George Mason UniversityGrandir - Fonds de solidarité pour l'enfanceHospices Civils de LyonHoward Hughes Medical InstituteInstitut MérieuxInstitut National de la Santé et de la Recherche MédicaleInstitut National du CancerIntegrative Biology of Emerging Infectious Diseases Laboratory of Excellence ANR-10-LABX-62-IBEIDJPB FoundationMeyer FoundationNCATS NIH HHS UL1 TR001866NIAID NIH HHS R01 AI088364NIH HHS R01AI088364NIH HHS UL1 TR001866REACTingRockefeller UniversitySCOR Corporate Foundation for ScienceSquare FoundationSt. Giles FoundationUniversity of Paris
Abstract
IFN-I and IFN-III immunity in the nasal mucosa is poorly characterized during SARS-CoV-2 infection. We analyze the nasal IFN-I/III signature, namely the expression of ISGF-3-dependent IFN-stimulated genes, in mildly symptomatic COVID-19 patients and show its correlation with serum IFN-α2 levels, which peak at symptom onset and return to baseline from day 10 onward. Moreover, the nasal IFN-I/III signature correlates with the nasopharyngeal viral load and is associated with the presence of infectious viruses. By contrast, we observe low nasal IFN-I/III scores despite high nasal viral loads in a subset of critically ill COVID-19 patients, which correlates with the presence of autoantibodies (auto-Abs) against IFN-I in both blood and nasopharyngeal mucosa. In addition, functional assays in a reconstituted human airway epithelium model of SARS-CoV-2 infection confirm the role of such auto-Abs in abrogating the antiviral effects of IFN-I, but not those of IFN-III. Thus, IFN-I auto-Abs may compromise not only systemic but also local antiviral IFN-I immunity at the early stages of SARS-CoV-2 infection.
Indexed as
AdultAgedAnimalsAntiviral AgentsAutoantibodiesChlorocebus aethiopsCOVID-19FemaleHumansInterferon Type ILongitudinal StudiesMaleMiddle AgedNasal CavityProspective StudiesSARS-CoV-2Antiviral AgentsAutoantibodiesInterferon Type I
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.